Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Biopharma Excellence's push for African vaccine equity is among 200+ successful vaccine-related projects to date


News provided by

Biopharma Excellence

Nov 30, 2022, 09:55 ET

Share this article

Share toX

Share this article

Share toX


In late June, PharmaLex's Biopharma Excellence team was invited to observe the signing of a Memorandum of Understanding (MoU) between Rwanda FDA and Ghana FDA, in recognition of its trailblazing work in accelerating global access to critical vaccines and pioneering treatments. This has included laying the foundations for localised vaccine manufacture in Africa. Biopharma Excellence's profound expertise in vaccine and other biopharmaceuticals regulation is not only helping its clients to get to market efficiently; it is also shaping the regulatory landscape - through the development of new concepts and solutions, eg for regulation of mRNA technologies.

FRANKFURT, Germany, Nov. 30, 2022 /PRNewswire-PRWeb/ -- PharmaLex Group's Biopharma Excellence service line, launched last year, has seen large-scale take-up of its vaccine expertise across more than 200 projects already delivered internationally. These have included creating an optimum environment to enable localised vaccine manufacturing in Africa, with a view to enabling greater equity in vaccine access across the continent. In June, linked to this, Biopharma Excellence was invited to witness the signing of a new Memorandum of Understanding (MoU) between Rwanda FDA and Ghana FDA, around the provision of reciprocal technical assistance related to medicines and vaccines manufacture regulatory oversight.

Since inception, the deeply experienced Biopharma Excellence team has successfully worked on a vast array of vaccine-related projects, working closely with clients including large and mid-sized pharma organizations and biotech startups, state institutions, non-profit organisations and academia, to streamline the path to market for these critical products.

This is a highly dynamic field at the forefront of science

Post this

The Biopharma Excellence team comprises specialist virologists, vaccinologists, molecular biologists, and leading ex-regulators with a rich understanding of the aetiology of infectious agents, as well as public health/health policy needs and expectations.

This impressive pool of in-house knowledge has enabled Biopharma Excellence to hone a precise vision of how the CMC, non-clinical and clinical development of novel vaccine technologies can be optimally blended with smart regulatory solutions worldwide. "We're in a very comfortable position to share our knowledge and to support interested developers to rapidly provide their solutions to the market," commented Dr. Michael Pfleiderer, lead scientist at Biopharma Excellence.

Against the backdrop of the still present SARS-CoV-2 (COVID-19) pandemic, demand for Biopharma Excellence's vaccine insights has been acute. The first vaccines were licensed with unprecedented speed - in a matter of months rather than years – supported by adapted, fit-for-purpose regulatory approaches. "Given this rapidly-evolving situation, fast, flexible, and innovative solutions have been - and continue to be – paramount," Dr Pfleiderer noted.

Since the onset of the pandemic, Biopharma Excellence has been deeply involved in all aspects of regulatory oversight of pandemic vaccines, and has developed comprehensive regional and global regulatory strategies for more than 20 SARS-CoV-2 vaccines, including novel platform technologies such as mRNA vaccines.

It has also supported pharma/biotech clients at all stages of development- from securing funding, partnering, CMC, non-clinical, clinical development all the way to successful fast-track approvals.

Its work to help establish vaccine manufacture and establish vaccine equity in Africa stems from an engagement with a major global brand, exploring how to localise vaccine manufacturing in Africa. The concept developed by Biopharma Excellence, which it dubbed Reg and Tech Transfer, has been accepted by pan-African organisations, and led to a contract to explore opportunities to enhance regulatory systems in the region. This is just one of a number of initiatives the team has been working on across the continent.

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence, under the PharmaLex brand. The global team of 70+ scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services geared to developers of biopharmaceuticals such as cell & gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars. It is headed up by Dr. Christian K. Schneider, formerly Chief Scientific Officer at the UK's MHRA, who is also its Chief Medical Officer.

Biopharma Excellence, which has already brought big business to Pharmalex, has shared its expertise and insights widely via published thought leadership on relevant issues ranging from Accelerated development and licensure of Coronavirus vaccines to Vaccine Development in Paediatric Populations – How to Proceed for SARS-CoV-2 Vaccines?.

Its expertise around vaccines has seen particularly pronounced demand, because of the field's unique characteristics. "This is a highly dynamic field at the forefront of science," Dr. Pfleiderer said. "It is subject to new technology, scientific progress, and new epidemics around the world, and it's inevitable that there will be a lag in the regulators' ability to adapt. That's why there's a need for experts like us who can adapt to these rapidly-changing situations. We understand that the procurement of vaccines is very different to any other product. They could be given to entire populations in a country or geographic region, so safety and clear communication about the science is paramount. Vaccines are paid for by governments too, which means that the entire infrastructure around it is different to other pharma categories."

-Ends-

About Biopharma Excellence
Biopharma Excellence by PharmaLex partners with biopharmaceutical companies on their journeys toward the development and delivery of scientific advances and product breakthroughs. Its worldwide team of experts comprises multidisciplinary scientists; specialists in cell and gene therapies, vaccines, monoclonal antibodies and process development; clinicians; and former regulators. Biopharma Excellence has a proven track record in developing solutions to the scientific, regulatory and commercialization challenges that are unique to biopharmaceutical companies. These global solutions are grounded in major regulatory markets across Europe, the United States and Australia. More at http://www.biopharma-excellence.com.

For further information, please contact:
Carina Birt, PR for Biopharma Excellence
[email protected]
+44 7970 006624

Media Contact

Anna LeGoff, Biopharma Excellence, 44 07799153550, [email protected]

SOURCE Biopharma Excellence

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.